Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 26, 25 | -0.04 Increased by +60.27% | -0.06 Increased by +20.55% |
| Aug 1, 25 | -0.19 Decreased by -280.00% | -0.23 Increased by +15.56% |
| Apr 7, 25 | -0.06 Increased by +82.86% | -0.15 Increased by +60.00% |
| Dec 31, 24 | -0.06 Increased by +62.50% | -0.15 Increased by +60.00% |
| Dec 18, 24 | -0.11 Decreased by -210.00% | -0.11 |
| Aug 28, 24 | -0.05 Increased by +88.64% | -0.18 Increased by +72.97% |
| Jun 24, 24 | -0.35 Decreased by -6.06% | -0.20 Decreased by -75.00% |
| Mar 29, 24 | -0.16 Increased by +42.86% | -0.20 Increased by +20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | N/A Decreased by N/A% | -2.35 M Decreased by -174.74% | - - |
| Mar 31, 25 | N/A Decreased by N/A% | -2.35 M Increased by +56.43% | - - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -1.80 M Increased by +38.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.15 M Decreased by -373.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -857.00 K Increased by +83.60% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.40 M Decreased by -84.82% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.95 M Increased by +6.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | 784.00 K Increased by +126.19% | Increased by +N/A% Decreased by N/A% |